Creative Planning Purchases 11,449 Shares of Guardant Health, Inc. $GH

Creative Planning grew its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 26.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,172 shares of the company’s stock after acquiring an additional 11,449 shares during the quarter. Creative Planning’s holdings in Guardant Health were worth $2,871,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Driehaus Capital Management LLC acquired a new stake in Guardant Health in the 1st quarter valued at $82,349,000. ARK Investment Management LLC lifted its stake in shares of Guardant Health by 100.4% in the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock valued at $146,935,000 after buying an additional 1,414,381 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after buying an additional 1,403,670 shares during the last quarter. Jennison Associates LLC bought a new stake in shares of Guardant Health during the second quarter worth about $37,233,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Guardant Health by 49.6% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030,638 shares of the company’s stock worth $105,674,000 after acquiring an additional 673,411 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Guardant Health news, insider John G. Saia sold 8,996 shares of Guardant Health stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $96.25, for a total value of $865,865.00. Following the sale, the insider owned 43,172 shares of the company’s stock, valued at approximately $4,155,305. The trade was a 17.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 313,161 shares of company stock worth $18,996,062. Insiders own 6.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Piper Sandler lifted their price target on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Barclays raised their target price on Guardant Health from $70.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. BTIG Research upped their price target on Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Finally, UBS Group lifted their price objective on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $77.14.

Guardant Health Trading Up 5.1%

Shares of GH opened at $105.42 on Monday. The stock has a 50 day moving average of $74.94 and a 200 day moving average of $58.76. The company has a market capitalization of $13.29 billion, a price-to-earnings ratio of -32.84 and a beta of 1.56. Guardant Health, Inc. has a 12 month low of $29.91 and a 12 month high of $110.00.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.